Karelizumab for Injection is effective in lymphoma, some advanced hepatocellular carcinoma, esophageal squamous carcinoma, and non-squamous non-small cell carcinoma. PD-1 receptor/body expressed by T cells binds to its ligands PD-L1 and PD-L2, which can inhibit T cell proliferation and cytokine production. PD-1 ligands are upregulated in some tumor cells, and signaling through this pathway can inhibit immune surveillance of tumors by activated T cells. Karelizumab is a human immunoglobulin G4 monoclonal antibody, which can bind to PD-1 receptor and block its interaction with PD-L1 and PD-L2, blocking the immunosuppressive response mediated by the PD-1 pathway, thus inhibiting tumor growth. Its indications are mainly: 1. patients with relapsed or refractory classical Hodgkin’s lymphoma who have undergone at least second-line systemic chemotherapy. 2. patients with advanced hepatocellular carcinoma who have previously received sorafenib treatment and/or oxaliplatin-containing systemic chemotherapy 3. Combination of pemetrexed and carboplatin is indicated for non-surgically resectable locally advanced or metastatic non-squamous non-small cell lung cancer that is mutation-negative for epidermal growth factor receptor gene and kinase-negative for lymphoma mesenchymal. 4. Patients with locally advanced or metastatic squamous esophageal cancer that has progressed or is intolerable after receiving first-line chemotherapy in the past 5. Patients with advanced nasopharyngeal carcinoma who have previously received second-line or higher chemotherapy with disease progression or intolerable disease 6. Patients with locally recurrent or metastatic nasopharyngeal carcinoma who are treated with a combination of cisplatin and gemcitabine. When using this drug, it should be used under the guidance of doctors, and should not be used blindly by oneself to avoid adverse effects.